Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer's disease.
about
Current Insights into Molecular Mechanisms of Alzheimer Disease and Their Implications for Therapeutic ApproachesAlzheimer mechanisms and therapeutic strategiesAllele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease.Multiplex Amplicon Quantification (MAQ), a fast and efficient method for the simultaneous detection of copy number alterations in neuroblastomaRecent insights into the molecular genetics of dementiaCurrent status on Alzheimer disease molecular genetics: from past, to present, to future.Understanding microRNAs in neurodegeneration.A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder.Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: insights from clinical trialsNext-generation DNA sequencing-based assay for measuring allelic expression imbalance (AEI) of candidate neuropsychiatric disorder genes in human brainPartial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer's disease transgenic mice.Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model.High glucose promotes Aβ production by inhibiting APP degradation.Genetics of Vascular Dementia.Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites.Role of common and rare APP DNA sequence variants in Alzheimer diseaseAPOE and AβPP gene variation in cortical and cerebrovascular amyloid-β pathology and Alzheimer's disease: a population-based analysis100 years and counting: prospects for defeating Alzheimer's diseaseCommon variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementiaMolecular genetics of Alzheimer's disease: an update.Contemplating effects of genomic structural variation.F-box only protein 2 (Fbxo2) regulates amyloid precursor protein levels and processing.The clinical context of copy number variation in the human genome.DNA methylation in neurodegenerative disorders: a missing link between genome and environment?Genetics of dementia: update and guidelines for the clinician.ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Aβ Secretion.Meserine, a novel carbamate AChE inhibitor, ameliorates scopolamine-induced dementia and alleviates amyloidogenesis of APP/PS1 transgenic mice.Opposite Dysregulation of Fragile-X Mental Retardation Protein and Heteronuclear Ribonucleoprotein C Protein Associates with Enhanced APP Translation in Alzheimer Disease.Modifications and Trafficking of APP in the Pathogenesis of Alzheimer's Disease.MicroRNAs can regulate human APP levels.Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients.Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease.Marginal vitamin A deficiency facilitates Alzheimer's pathogenesis.The genetic architecture of autism spectrum disorders (ASDs) and the potential importance of common regulatory genetic variants.Amyloid precursor protein gene (APP) variation in late-onset Alzheimer's disease.
P2860
Q22241945-777E8D96-6157-49F0-9124-10A4AB2C3069Q22252311-416407F7-7815-4518-97E6-20D88B2CC288Q30493543-A537CFA5-FF72-456A-B169-3D5D39CD9F6FQ33575683-6519FBB3-D0C5-4D1D-A1B5-EFB9D9394BE3Q33830518-10C997A6-117C-4ADD-A276-AE4E60F64731Q33871345-D9619C90-C26A-44D2-A913-828A4CFA3DD7Q33995527-81E630AA-D311-4444-AA45-5BF87593096FQ34005558-156474AB-CE76-4C09-898E-803F4D798EFBQ34014237-AECB6C20-ED5A-420A-9466-1C534850ACDCQ34052418-518FB638-9317-4CBD-B62B-76CF03D18B66Q34067152-870529B4-349C-4F89-B282-7B0AC1A2C813Q34584517-3384A539-FB72-4B6C-8C7E-82F62D00BAD2Q34874591-A00F86C6-F772-4018-A1E5-A04C8D3B5206Q35094704-94B9A818-B8D2-4FFA-89D8-BB1A10BC4FEAQ35693893-4CA9F514-9837-4CDE-BD49-941BB419449DQ35883202-66D58A61-41C7-44A6-885B-9081E91188A8Q36452227-4E505629-7696-4FE7-BD1F-2C307B121993Q36643419-6AEC9D05-04E4-4E92-BE31-4AD88C250797Q36967985-8E28E6CF-BE21-4BCD-BDD8-724B120A54D3Q37209771-7A9C96C0-D467-4B56-A279-C4DDC6AF2A7EQ37315301-99AE83A8-C3A1-4559-BAAB-E6FA02F8EEBBQ37622647-DA3F0533-5169-4190-920C-FADF17C89931Q37704614-1D538594-0D7B-49CF-A35F-1696DAFFC18DQ37872024-9DF4FBDB-F6E5-4F43-9887-614A875B51D1Q38027808-CD074CE0-2491-4E3F-A2C5-AD450B07E086Q39006798-D93E3BA7-F045-4302-9040-22A6415F0CE2Q39054244-CF133CF3-B8D6-48F6-8471-2621D5B1D946Q40863954-3764B0B5-918F-4374-B33F-51CEC544C875Q41665323-0D967243-B106-44B7-8250-6E9745583BC2Q42426890-8B186DDA-D5FB-404F-BFDA-E666D11C03C0Q42642426-BCB8938C-0BC5-473C-BAE9-646922BD971DQ47431150-392C9613-B121-4928-9F9E-B0FE5F9EB686Q48302187-44F15AD7-1E9A-49EF-B743-23E8DC328E92Q50345695-4AE242CA-A2FF-46FD-9578-E62591D0897AQ53317692-2B5B1C0F-0FC5-4E6C-A1BD-E075C76939EC
P2860
Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer's disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Genetic risk and transcription ...... rotein in Alzheimer's disease.
@en
Genetic risk and transcription ...... rotein in Alzheimer's disease.
@nl
type
label
Genetic risk and transcription ...... rotein in Alzheimer's disease.
@en
Genetic risk and transcription ...... rotein in Alzheimer's disease.
@nl
prefLabel
Genetic risk and transcription ...... rotein in Alzheimer's disease.
@en
Genetic risk and transcription ...... rotein in Alzheimer's disease.
@nl
P2093
P50
P356
P1433
P1476
Genetic risk and transcription ...... rotein in Alzheimer's disease.
@en
P2093
Ellen Corsmit
Evelyn De Leenheir
Jean-Jacques Martin
Kenan Kamali
Kristel Sleegers
Peter P De Deyn
Sally Serneels
Veerle Bogaerts
P304
P356
10.1093/BRAIN/AWL212
P407
P577
2006-08-24T00:00:00Z